mbbirdy
Barclays on Thursday downgraded the contract research organizations IQVIA Holdings (NYSE:IQV), ICON PLC (NASDAQ:ICLR), and Fortrea Holdings (NASDAQ:FTRE), arguing that the Trump administration’s potential pharma-specific tariffs can lead to biopharma reorganization, hurting CROs’ top topline.
Analyst Luke Sergott downgraded IQVIA (